RT Journal Article
SR Electronic
T1 Focal amplification of <em>FAL1</em>, an oncogenic enhancer lncRNA mapping to chromosome 1q is associated with dysregulated BMI1/p21 axis and an adverse event in intracranial ependymomas
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.24.21254063
DO 10.1101/2021.03.24.21254063
A1 Malgulwar, Prit Benny
A1 Pathak, Pankaj
A1 Sharma, Vikas
A1 Jha, Pankaj
A1 Nambirajan, Aruna
A1 Rajeshwari, Madhu
A1 Singh, Manmohan
A1 Suri, Vaishali
A1 Sarkar, Chitra
A1 Sharma, Mehar Chand
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.24.21254063.abstract
AB Gain of chromosome 1q locus is a common cytogenetic feature associated with intracranial ependymomas; however, candidate non-coding RNAs on this locus have not been identified. Recent studies have reported somatic copy number alterations for long non coding RNA (lncRNA) FAL1/FALEC residing on chromosome 1q to stabilize BMI1, an epigenetic repressor and PRC1 component, leading with to downregulation of p21/CDKN1A tumor suppressor gene. We aimed to study the role of FAL1 in ependymomas, its association with 1q gain, BMI1/p21 regulatory axis and clinicopathological parameters. Using SNP array analysis (GSE32101), 31% (discovery cohort) and 63.8% (in-house cohort) showed amplification/gain of FAL1 locus with higher prevalence in intracranial tumors. Copy number gain of FAL1 locus was significantly associated with increased FAL1 (p=0.003) and BMI1 (p=0.007) levels, and reduced p21 (p=0.001) expressions. Interestingly, gain of FAL1 locus and FAL1 transcripts did not show any association with 1q gain or RELA fusions. Subcellular localization reported FAL1 to be expressed in nuclear compartment in ependymomas. Chromatin immunoprecipitation-qPCR demonstrated in-vivo binding of BMI1 at p21 promoter locus with BMI1 target genes to be enriched in cell architecture related pathways. A 3-tier survival analysis between FAL1 gain and increased expression levels of FAL1 and BMI1 correlated with poor outcome in our cohort. Ours is the first study demonstrating gain of FAL1 locus and its interplay with the BMI1/p21 axis in intracranial ependymomas. Further studies into this epigenetic regulatory mechanism will unravel novel driver mutations in intracranial ependymomasHighlights Somatic variations in enhancer long non-coding RNA has been recently attributed for various clinical malignancies including cancers. Gain of 1q locus is a common cytogenetic variation observed in intracranial ependymomas. Our study has demonstrated, focal amplification of enhancer lncRNA mapping to Chromosome 1q, FAL1/FALEC, to be involved in oncogenicity/ progression of ependymomas. Moreover, our data suggests a positive association with BMI1 (a PRC1 component) with FAL1 levels, indicating downregulation of BMI1 target gene involved in cell cycle, p21. Furthermore, a 3-tier prognosis analysis (between FAL1 gain, FAL1 and BMI1 expressions) suggests a negative survival outcome. Our study highlights the importance of somatic variation in non-coding genome with ependymoma survival.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are thankful to Neuro Sciences Centre, AIIMS and Science and Engineering Research Board (SERB) (EMR/2016/003365) for financial support; all consultants from the Departments of Pathology and Neurosurgery, AIIMS; all technical staff from the Neuropathology laboratory, AIIMS and Indian Council of Medical Research(ICMR), for Senior Research Fellowship award to Prit Benny Malgulwar (No.3/2/3/284/2014/NCD-III). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was ethically approved by the AIIMS Institute Ethics Committee (Ref No: IESC/T-211/05/05/2015).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSNP array analysis was performed using publically available data on GEO for pediatric ependymoma using GSE32101. The list of 47 ependymomas with their genetic alterations can be found in Supplementary Table-2